IMHO any valuation needs to be made on the basis of an estimation of cashflows over the med-long term (this applies to every stock). In CHM's case, you can't use the metrics you quoted as a basis for projecting cashflows. Read any analyst report on any early stage biotech and you will see what methods they use to predict these cashflows - they don't involve those metrics.
- Forums
- ASX - By Stock
- My analysis and intrinsic value of CHM March 2022
IMHO any valuation needs to be made on the basis of an...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
|
|||||
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.76M |
Open | High | Low | Value | Volume |
1.8¢ | 1.9¢ | 1.8¢ | $7.224K | 394.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 524782 | 1.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.9¢ | 579591 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 524782 | 0.018 |
3 | 707660 | 0.017 |
12 | 3472701 | 0.016 |
13 | 4840065 | 0.015 |
5 | 2331428 | 0.014 |
Price($) | Vol. | No. |
---|---|---|
0.019 | 579591 | 4 |
0.020 | 1114755 | 4 |
0.021 | 488333 | 3 |
0.022 | 300000 | 2 |
0.023 | 155000 | 2 |
Last trade - 15.32pm 12/07/2024 (20 minute delay) ? |
Featured News
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
CHM (ASX) Chart |